At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 100 target
Drug / intervention
Erlotinib w Concurrent Radiotherapy +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Erlotinib Versus Etoposide Plus Cisplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) With Activating Mutation of Epidermal Growth Factor Receptor (EGFR) in Exon 19 or 21
In Brief
A Phase 2 clinical trial evaluating Erlotinib w Concurrent Radiotherapy and etoposide/cis-platin (EP) w Concurrent Radiotherapy for Non-small Cell Lung Cancer. Targeting 100 participants across 19 sites.
Detailed Summary
Erlotinib with concurrent radiotherapy has superior efficacy and comparable safety profile in unresectable stage III non-small cell lung cancer (NSCLC) patients with activating mutation of epidermal growth factor receptor (EGFR) in exon 19 or 21 versus etoposide plus cis-platin with concurrent radiotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
CollaboratorsRoche Pharma AG
Timeline
Phase 2UnknownOverdue
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartDec 2012
Primary CompletionAug 2018
Study CompletionOct 2018
TodayJul 2026
First PostedOct 26, 2012
Enrollment StartDec 14, 2012
Primary CompletionAug 20, 2018
Study CompletionOct 20, 2018
TodayJul 1, 2026
Enrollment to primary: 5.7 yearsPosted 13.7 years ago
Interventions
Erlotinib w Concurrent Radiotherapyother
etoposide/cis-platin (EP) w Concurrent Radiotherapyother
Etoposide / Cis-platin w Concurrent Radiotherapy